Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00355251|
Recruitment Status : Terminated (On the basis of published results of SMART study, it has been observed that the results are worse in patients who have interrupted their treatments.)
First Posted : July 21, 2006
Last Update Posted : March 20, 2014
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Atorvastatin 40 mg/Atorvastatin 80 mg||Phase 4|
Recently, the inhibitory effect of the statins on the replication of the human immunodeficiency virus Type 1 (HIV-1) through two independent mechanisms of action has been described: the blockade of Rho guanosine triphosphatase that intervenes in the entry and exit of the virus and the blockade of the interaction between LFA-1 (leukocyte function antigen 1) and its ICAM 1 ligand (intercellular adhesion molecule 1) that intervenes in the process through which the virus binds to the target cell.
These initial data have led to the study of the effect of atorvastatin on the plasma replication of HIV in HIV+ patients that interrupt antiretroviral therapy (Ator Study 3) developed in our unit. The data of this study indicate that baseline plasma cholesterol determines viral load rebound on interrupting antiretroviral treatment. However, the introduction of atorvastatin on the day of interruption provided no virological or immunological benefit in comparison with an interruption of antiretrovirals without statins. This may be due to the fact that the potent inhibitory effect of atorvastatin is unable to compensate their activating effect on the production of HIV also described in our study.
Overall, our results pose a possible usefulness of atorvastatin in the control of viral replication if given before the interruption of antiretroviral therapy due to:
- Their capacity to reduce serum cholesterol at the time of interruption and consequently the cholesterol of the cell membrane.
- Their potent capacity to purge the HIV reservoir
Therefore, in this study we aim to investigate the impact of atorvastatin on viral replication when it is given 8 weeks before the interruption of the antiretroviral treatment and determine whether this impact is due to the reduction in serum and/or membrane cholesterol, or whether, on the other hand, there is a contribution by atorvastatin's capacity to induce the expression of viral products.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the Influence of Atorvastatin in Plasma Viral Replication Given Prior to Antiretroviral Treatment Interruption in Patients With HIV-1 Infection and Viral Suppression.|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||February 2007|
4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
Drug: Atorvastatin 40 mg/Atorvastatin 80 mg
Atorvastatin 40 mg/80 mg
No Intervention: B
4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
- The primary endpoint is viral load (HIV RNA) in plasma. [ Time Frame: at 12 and 24 weeks ]
- CD4 and CD8, absolute value, percentage and activation. [ Time Frame: during the 32 weeks of follow-up ]
- Total cholesterol, HDL and LDL in serum. [ Time Frame: during the 32 weeks of follow-up ]
- Cholesterol in cell membrane. [ Time Frame: during the 32 weeks of follow-up ]
- Symptoms reported by the patient following the interruption of the HAART therapy or signs detected by the clinician (classification according to the WHO), mainly those which may indicate acute antiretroviral symptoms. [ Time Frame: during the 32 weeks of follow-up ]
- Creatinine, urea, creatine kinase (CK), hepatic tests, (AST, ALT, GGT) [ Time Frame: during the 32 weeks of follow-up ]
- Proviral load. [ Time Frame: during the 32 weeks of follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00355251
|Germans Trias i Pujol Hospital|
|Badalona, Barcelona, Spain, 08916|
|Principal Investigator:||Bonaventura Clotet, MD,PhD||LLuita contra la Sida Foundation-HIV Unit|